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Potential clinical significance of the study in terms of clinical need, goals and how the 
study moves the field forward 
Individualised cardiovascular risk prediction remains an unmet clinical need in patients with 
hypertension and other risk factors. Studying multiple biomarkers at a time, proteomics has 
the potential to detect subclinical disease and thereby improve risk stratification and targeted 
treatment. In the present study we have taken our clinical proteomic studies into coronary 
artery disease one step further, from a cross-sectional study to prediction, by evaluating the 
potential of a panel of urinary polypeptides to predict future coronary events.  
Abstract 
Purpose: We have previously demonstrated associations between the urinary proteome 
profile and coronary artery disease (CAD) in cross-sectional studies. Here we evaluate the 
potential of a urinary proteomic panel as a predictor of CAD in the Hypertensive 
Atherosclerotic Cardiovascular Disease (HACVD) sub-study population of the ASCOT 
study.  
Experimental design: Thirty-seven cases with primary CAD endpoint were matched for sex 
and age to controls who had not reached a CAD endpoint during the study. Spot urine 
samples were analysed using capillary electrophoresis (CE) coupled to Micro-TOF mass 
spectrometry (MS). A previously developed 238-marker CE-MS model for diagnosis of CAD 
(CAD238) was assessed for its predictive potential. 
Results: Sixty urine samples (32 cases; 28 controls; 88% male, mean age 64±5 years) were 
analysed. There was a trend towards healthier values in controls for the CAD model classifier 
(-0.432±0.326 vs -0.587±0.297, P=0.170), and the CAD model showed statistical 
significance on Kaplan-Meier survival analysis P=0.021. We found 190 individual markers 
out of 1501 urinary peptides that separated cases and controls (AUC>0.6). Of these, 25 
peptides were also components of CAD238. 
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Conclusion & clinical relevance: A urinary proteome panel originally developed in a cross-
sectional study predicts CAD endpoints independent of age and sex in a well controlled 
prospective study.  
Introduction 
Cardiovascular disease is the leading cause of morbidity and mortality in the United 
Kingdom and worldwide (1;2). Cardiovascular risk assessment and risk prediction are 
performed daily in primary and secondary care with traditional scoring methods combining 
classical risk factors such as age, sex, smoking, blood pressure and cholesterol. These 
methods calculate average percentage likelihood of a patient suffering a cardiovascular event 
(acute coronary syndrome, stroke or transient ischaemic attack) (3-5) and assist the clinician 
in guiding initiation and intensity of therapies (4). However, such individual risk assessments 
are not always precise. The main challenge of cardiovascular risk stratification currently lies 
with patients who are classified as being at intermediate risk by conventional methods (6). 
More refined methods of risk assessment, especially for those at intermediate risk, are 
therefore required. 
 
Established cardiovascular disease is preceded by an asymptomatic phase (7)
 
and the 
identification of precursors of cardiovascular disease may allow the detection of damage at an 
early and potentially reversible stage (8). Biomarkers are an example of one such tool to 
better identify high-risk individuals, to diagnose disease conditions promptly and accurately, 
and to provide a prognosis and treat patients effectively (2).  
Most available biomarkers have been developed as an extension of targeted physiological 
studies, investigating known pathways. By contrast, emerging technologies are beginning to 
allow the systematic, unbiased characterization of variation in proteins associated with 
disease conditions (9). Urine is a promising medium for proteomic-based research as it is 
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easily accessible and stable when frozen without requiring special preparation (10;11). We 
have previously reported and validated the use of urinary proteomics in the diagnosis of 
coronary artery disease (CAD) (12). Urinary proteomic biomarkers have also been studied in 
other conditions such as preeclampsia (10), diabetes (13), diabetic nephropathy (14) stroke 
(15) and heart failure (16). We hypothesised that a CAD-specific urinary polypeptide panel 
not only predicts the presence or absence of disease, but also, critically, future cardiovascular 
events, an observation that would extend current cross-sectional studies. In order to address 
this question we used urine samples available from the Anglo-Scandinavian Cardiac 
Outcomes Trial (ASCOT), an investigator-led, multicenter, randomized trial to compare 
treatment strategies for the prevention of CAD in patients with hypertension who had 
multiple risk factors (see below for inclusion and exclusion criteria) (17). 
Methods  
Patients 
The aim of ASCOT was to determine the answers to several questions regarding the 
management of hypertension, particularly whether combination therapy with a 
dihydropyridine calcium channel blocker and angiotensin-converting enzyme (ACE) inhibitor 
produced greater benefits in terms of reducing coronary heart disease events than the standard 
beta-blocker and diuretic combination (17). It also sought to determine whether lipid 
lowering with a statin provided additional benefit in those hypertensive patients with average 
or below average levels of serum total cholesterol. Recruitment ran from February 1998 to 
May 2000 by which time 19,342 hypertensive patients had been randomized to the two 
antihypertensive treatment regimes. Methods & study design of ASCOT have been described 
in detail elsewhere (18). 
Randomization was to either a standard antihypertensive regimen (β-blocker + diuretic) or to 
a more contemporary regimen (calcium antagonist + angiotensin converting enzyme 
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inhibitor). Patients were ineligible if they had any of the following: previous myocardial 
infarction, currently treated angina, a cerebrovascular event within the previous 3 months, 
congestive heart failure, uncontrolled arrhythmias, or any major non-cardiovascular disease. 
In addition, the benefits of cholesterol lowering in the primary prevention of coronary heart 
disease in hypertensive patients were assessed in a lipid-lowering arm of this trial (ASCOT-
LLA). A total of 10,350 patients with a non-fasting cholesterol level of ≤ 6.5 mmol/L were 
recruited into ASCOT-LLA, and randomized to either atorvastatin 10 mg or placebo (19).  
A nested case-control design was used. The population examined in this study was the 
Hypertension Associated Cardiovascular Disease (HACVD) cohort; an intensively 
phenotyped sub-study of  (ASCOT) (20). The HACVD sub-study involved intensive 
phenotyping of 1,395 subjects, along with DNA collection, with the intention of identifying 
unrecognised genetic influences on the development of hypertension associated 
cardiovascular disease (20). Baseline demographic data (age, gender and ethnicity), levels of 
cardiovascular risk factors (cigarette smoking, diabetes, dyslipidaemia, blood pressure and  
body mass index), evidence of target end-organ damage (echocardiography and 
electrocardiographic criteria of left ventricular hypertrophy, carotid intima-media thickness 
and proteinuria) and previous history of cerebrovascular events or peripheral vascular disease 
were recorded for all patients.  
Repeat office blood pressure levels, repeat lipid levels, medication usage, antihypertensive 
treatment, statin therapy, and aspirin use were recorded throughout the trial, as were outcome 
measures of the composite endpoint which included all cardiovascular events and procedures 
plus development of renal impairment. Urine samples, collected in the morning after an 
overnight fast (10 to 12 hours), were tested for blood, sugar and protein, then divided into 
aliquots and stored at -20°C until analysed. 
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The study was approved by the ethics committee at St Mary’s Hospital, London and 
Beaumont Hospital, Dublin (REC# 99/21), and adheres to the principles of the Declaration of 
Helsinki. All patients gave written informed consent. 
In this proteomics study, we adopted a nested case-control design within the HACVD 
substudy of the ASCOT trial. The primary endpoint in this study was CAD, the definition of 
which included the following endpoints: fatal CAD, symptomatic non-fatal myocardial 
infarction (MI) and coronary revascularisation. Controls for cases were individuals who had 
not experienced a cardiovascular disease endpoint during the study period (median 
observation time 5 years). All cases and controls were defined by presence of a urine sample 
from 1-1.5 years post-randomisation, stored for biomarker assay. 87% of patients were white-
European and to exclude any effects of ethnicity, selection of cases and controls was 
restricted to this group. Subjects with established cardiovascular disease at baseline 
(including previous history of stroke, transient ischaemic attack, peripheral vascular disease) 
were excluded from this prospective study. 
All remaining eligible cases (N=37) from the HACVD cohort were included in this study, 
and matched (1:1) for age (± 2 years), sex, smoking, diabetes, and the same treatment arm of 
the ASCOT study, as described in Figure 1.  
Urinary Proteomics 
Sample Handling 
Samples were prepared as described previously (12). A 0.7mL aliquot of urine was diluted 
with 0.7mL of 2 mmol/L urea and 10 mmol/L NH4OH containing 0.02% SDS. Proteins with 
a molecular mass >20kDa were removed by filtering of samples using Centrisart 
ultracentrifugation filter devices (Sartorius, Gottingen, Germany) at 3000g until 1.1mL 
filtrate was obtained. The filtrate was applied onto a PD-10 desalting column (Amersham 
Bioscience) equilibrated with 0.01% NH4OH to remove urea, electrolytes and salts, and to 
enrich the polypeptides present. Before analysis all samples were lyophilized, stored at 4
o
C, 
and resuspended in high-performance liquid chromatography-grade H2O.  
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CE-MS Studies 
Capillary-electrophoresis (CE) coupled to mass spectrometry (MS) enables reproducible, 
robust, high resolution analysis of several thousand low molecular weight urinary 
proteins/peptides (21).  CE-MS was performed as described previously (12) using a P/ACE 
MDQ capillary electrophoresis system (Beckman Coulter) online coupled to a time-of-flight 
mass spectrometer (microTOF; Bruker Daltonic). Data acquisition and MS acquisition were 
automatically controlled by the CE via contact close relays. Spectra were accumulated every 
3 seconds over a range of mass-to-charge ratios from 350 to 3000. 
Data processing 
Data were analysed using Mosaiques-Visu software; CE-MS peaks were detected using a 
signal-to-noise ratio of at least 4. The charge of each peak was calculated based on isotopic 
distributions and conjugated masses. Data were deconvoluted and mass spectral ion peaks 
from the same molecule at different charge states were combined and recorded as a single 
mass. MS data were normalized as described previously (22) to correct for technical variation 
such as signal suppression as well as biological variation such as differing urine 
concentrations due to hydration status of the patient at time of collection. In particular, 
reference signals of >1700 urinary peptides were used for CE time calibration and MS signal 
intensities (ion counts) were normalized relative to 29 “housekeeping” peptides with small 
relative standard deviation. For time-of-flight MS mass calibration, 80 reference masses 
exactly determined by Fourier transform ion cyclotron resonance mass spectrometry were 
used. The resulting peak list characterizes each peptide by its molecular mass (Da) and CE 
migration time, normalized signal intensities are used as measure for relative abundance. 
Data were entered into a Microsoft SQL database for comparison with other samples and for 
further analysis. MS peaks from different samples were presumed identical if mass deviation 
was ≤50 ppm for small or ≤75 ppm for larger peptides, and the migration time deviation was 
2 minutes.  
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Data analysis 
Our group have previously developed a 238-peptide panel (CAD238) using CE-MS which is 
associated with CAD in a cross-sectional study (12). This panel was assessed for its 
predictive value in this study.  For comparison, three other models, devised in a similar 
manner (for chronic kidney disease (CKD273) (23), heart failure (16) and stroke (15)) were 
also assessed in this population for their predictive values. A numerical value, known as a 
“classification factor”, was generated using Mosaiques Visu software for more 
straightforward statistical analysis of the resulting polypeptide picture for each individual 
subject; lower classification factor values considered to be “healthier”. Cases and controls 
were compared using paired t-test and linear regression analyses. We then performed survival 
analysis to determine whether classification factors from the urinary proteomic panel could 
be predictive of cardiovascular events using the CAD238 model. Classification factors were 
split into values greater than the mean, and less than the mean for each model. We also 
performed survival analysis, in the same way, for classification factors from other previously 
derived models for CKD, heart failure and stroke as negative controls. We were not expecting 
these panels to be of use in discriminating between cases and controls for coronary artery 
disease.  
Statistical Analysis 
Analysis of clinical parameters and the classification factors derived from urinary proteome 
analysis were performed using SPSS software, (IBM SPSS Statistics for Windows, Version 
19.0. Armonk, NY: IBM Corp). Parametric and non-parametric tests for comparison between 
groups were applied as appropriate. Data are given as mean±SD, median (interquartile range) 
or percentage as appropriate.  Comparisons were made using paired t-test, McNemar’s test 
and linear regression as appropriate. Kaplan-Meier survival analysis was performed to 
compare classification factors and likelihood of experiencing a cardiovascular event. The 
non-parametric Mantel Cox logrank test was used to compare survival distributions between 
groups according to CAD238 classifier (</>mean, as described below).Cox proportional 
hazards analysis was used to analyse the effect of CAD classifier along with other covariates 
on survival.  P-values <0.05 were considered significant and AUC cut off  >0.6 was used. 
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Results 
Of the 37 cases and 37 matched controls included in this study, sixty urine samples passed 
quality control for proteomic analysis (Table 1, Figure 1). These 60 samples comprised 32 
cases who experienced CAD events and 28 controls, with 88% male and a mean age 64±5 
years (Table 1). There were no significant differences in mean age, gender, blood pressure, 
cholesterol, smoking history or drug treatment arms between cases and controls.  
The CAD238 classifier appeared to be different between cases with CAD events and controls 
at baseline (-0.432±0.326 vs -0.587±0.297) although the difference was not statistically 
significant (P=0.170).  
We then performed survival analysis to assess the model in its ability to detect cases from 
controls at a given classifier level cut-off.  We used mean classifier value to divide subjects 
into two groups; those with a classifier value of greater than the mean were compared with 
those with classifier values below the mean. The Mantel Cox test revealed a significant 
difference between the hazard functions of the two groups (test statistic 5.35, P-value 0.021) 
for the CAD238 model (Figure 2). Cox proportional hazards model with age and gender as 
covariates revealed that the hazard for CAD score >mean was 2.38 times that of those <mean, 
p-value 0.017.  As expected, on further survival analysis of matched (age, gender, treatment 
arm, diabetes, smoking status) and unmatched (blood pressure, cholesterol level) variables, 
no other variable showed significant differences between groups with vs without CAD events 
(data not shown). 
In order to confirm the predictive value of the CAD238 panel for the specific outcomes in this 
study we also tested proteomic panels related to other conditions. As expected, the panels that 
predict CKD, heart failure and stroke were neither different at baseline (cases vs controls: -
0.069±0.388 vs -0.095±0.236, P=0.927; 0.282±0.663 vs 0.114±0.569, P=0.333; and -
0.114±0.679 vs -0.140±0.528, P=0.873, respectively) (Supplementary Figure S1) nor on 
survival analysis (log rank Mantel-Cox P=0.690, P=0.386, and P=0.874, respectively), for 
the outcome "CAD event" (Supplementary Figure S2).  
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We subsequently unblinded the cohort and studied all  urinary polypeptides identified on CE-
MS analysis individually. We found 190 individual peptides out of 1501 urinary peptides that 
were different between cases and controls at baseline at the AUC > 0.6  cut-off 
(Supplementary Table S1). Many of these peptides have previously been associated with 
cardiovascular disease, most notably fragments of collagens. 
Twenty-five of these 190 peptides were also components of the 238 peptides comprising the 
CAD238 panel (Table 2), including fragments of membrane associated progesterone receptor 
component 1 (PGRC1), prostaglandin-H2 D-isomerase (PTGDS), collagen alpha-1(I) chain 
(CO1A1), collagen alpha-1(III) chain (CO3A1), collagen alpha-1 (XVI) chain (COGA1), 
plexin domain-containing protein 2 (PXDC2), beta 1,3 - galactosyltransferase 6 (B3GT6) and 
retinol-binding protein 4 (RBP4).  
Discussion 
We have already used CE-MS based urinary proteomics in our clinical studies in a wide 
range of conditions (15;16;23;24). The relatively high throughput with this technique, the 
stability of the urinary proteome and the non-invasiveness of urine sampling are some of the 
key advantages of this approach. Given the large number of biomarkers that can be assessed 
with proteomics it is not unreasonable to propose that they provide information on different 
pathophysiological aspects of the conditions including earlier and later steps in disease 
development. We have therefore proposed that proteomic biomarkers can be used both to 
detect early stages in the disease process and to predict development of more advanced stages 
including clinically overt disease in asymptomatic patients.  
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The most robust data to support this hypothesis derives from our work in chronic kidney 
disease where a panel of 273 urinary biomarkers (CKD273) has been found to differentiate 
between patients with normal and impaired renal function (25). The same panel has been 
found to predict the development of chronic kidney disease. In particular Roscioni et al. (26) 
have shown that it predicts the development of diabetic nephropathy in patients with type 2 
diabetes earlier and with greater sensitivity and specificity than currently used predictors, 
including microalbuminuria. Similarly, we have recently shown that a proteomic signature 
that was developed in patients with diastolic dysfunction but without symptoms of heart 
failure also differentiates between patients with overt heart failure and healthy controls (16), 
demonstrating that pathophysiological processes that provide a link between early and 
advanced disease processes can be represented in the urinary proteomic signatures. We have 
excluded people with a history of stroke and have therefore not looked at stroke events. The 
stroke panel itself was originally derived to differentiate acute stroke from stroke-like 
conditions. We used it here as a negative control. We also used the heart failure and CKD 
panels used in this manner as we were similarly not expecting positive findings for these 
panels in our study. Reassuringly these panels were negative in predicting between cases and 
controls for coronary artery disease. 
 
In the present study we have taken our clinical proteomic studies into CAD one step further, 
from a cross-sectional study to prediction by evaluating the potential of a panel of urinary 
polypeptides to predict future coronary events. This panel (CAD238) was developed and 
extensively validated in cross-sectional studies of patients with CAD vs healthy controls. In 
order to provide the best balance between sensitivity and specificity the model was built on 
data from patients with a wide range of disease severity (12), covering therefore early and 
more advanced disease processes. The main result of the present study is that in patients who 
www.clinical.proteomics-journal.com Page 12 Proteomics - Clinical Applications 
 
This article is protected by copyright. All rights reserved. 
 
do not have overt cardiovascular disease at baseline but are at risk to develop such disease 
and associated events due to their risk profile, the CAD238 panel differentiates between 
patients who had CAD events within the study period and those who did not. The nested 
case-control design of our study allowed for rigorous matching for cardiovascular risk factors 
and treatment arm. By matching on such major risk factors, the potential for confounding was 
considerably reduced. We used the ASCOT study specifically because one might reasonably 
have predicted cardiovascular events to occur in this cohort with higher-than-average 
prevalence of CAD risk factors (18).  
We have also demonstrated that not all of the 238 markers in the original CAD238 panel are 
significantly associated with CAD events. Looking at all urinary polypeptides, 25 of the 190 
markers that were differentially expressed between cases and controls were also part of the 
CAD238 panel. We are not surprised about this seemingly small overlap. The CAD238 panel 
was developed to represent different stages of CAD severity including triple vessel CAD 
requiring CABG surgery which was not the case in the patients selected for the present study. 
It appears therefore plausible that only some of the markers in the CAD238 panel were found 
to be different between cases and controls in our present study, and it can be hypothesised 
that these markers reflect earlier stages of CAD that had the potential to progress to clinically 
overt disease during the course of the follow-up period. 
It is also important to highlight the fact that these proteins are derived not only from the 
kidney, but potentially from all organs. In this way the urine can depict systemic processes 
such as turnover in the extracellular matrix and the pattern may change over time and 
depending on the disease (14). The urinary biomarkers identified relate to key molecular 
components of CAD. Indeed collagen types 1 and 3 have previously been found in urinary 
proteomic studies relating to cardiovascular disease (12). This study found decreased urinary 
excretion of certain collagen type 1 and 3 alpha chain fragments but increased excretion of 
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specific collagen type 1 and 3 alpha chain fragments with a C-terminal GxPGP motif.  
Another example is retinol-binding protein 4 (RBP4) which has been associated with 
metabolic syndrome in both sexes, prior cerebrovascular disease in men, and it is also thought 
that circulating RBP4 could be a marker of metabolic complications, atherosclerosis and 
cardiovascular disease (27;28). RBP4 is an adipokine, and there is emerging evidence that 
they are involved in the development of cardiovascular disease. This is not surprising as they 
are already known to provide a link between insulin resistance, obesity and inflammation 
(29). The adipokine zinc-alpha-2-glycoprotein (ZA2G) was also identified among the 25 
urinary polypeptide markers showing significant difference between cases and controls. 
Fibrinogen beta chain was also found to be different which is unsurprising considering that 
beta-chain synthesis is a key step in the production of mature fibrinogen (30). Fibrinogen is 
known to play an important role in inflammation, atherogenesis and thrombogenesis. Several 
polymorphisms have been identified in the fibrinogen chain genes that determine plasma 
levels of fibrinogen, however, plasma fibrinogen level and cardiovascular risk may be more 
dependent on interactions with environment and genetics (e.g. moderate alcohol intake may 
lower plasma fibrinogen concentration) (30). 
Even in light of the pathophysiological significance of individual protein fragments we would 
like to reinforce the message that for immediate clinical diagnostic and prognostic purposes 
the global view on a panel of proteomic markers may be of greater importance than 
individual markers, although their pathophysiological relevance is reassuring. Another stream 
of information may derive from the proteases that are responsible for the generation of 
specific urinary peptides from their source proteins. Protease activity prediction has been 
proposed previously and appropriate tools have been developed (31). It would be beyond the 
scope of this study that was designed to take a cross-sectional proteomic classifier to 
longitudinal prediction to predict and validate protease activity but we would like to reinforce 
the message that the urinary proteome provides information beyond individual peptides, 
peptide patterns and source proteins. 
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The principal limitation of the study is that of a relatively small sample in a nested case-
control design. Clearly a larger study will need to be performed to get a better impression of 
the potential predictive value in a clinical setting. We also acknowledge that our data have 
not been replicated in an independent cohort. On the other hand, we have applied extremely 
strict criteria for the selection and matching of cases and controls and performed the CE-MS 
analysis in a blinded fashion. We used samples from a well controlled clinical trial with 
validated endpoints adding further strength to the design. 
Concluding remarks 
Individualised cardiovascular risk prediction remains an unmet clinical need in patients with 
hypertension and other risk factors. In a sub-study of the ASCOT study we have shown that a 
panel of urinary polypeptides that was originally developed to differentiate between patients 
with and without CAD can also be predictive of coronary events in asymptomatic subjects 
with hypertension. Studying multiple biomarkers at a time, proteomics has the potential to 
detect subclinical disease and thereby improve risk stratification and targeted treatment. 
A number of questions remain to be answered to clarify the clinical utility of this proteomic 
panel. These include how best to identify patients who would benefit from proteomic testing, 
the positive and negative predictive values of the test, and the comparison of proteomics with 
other emerging biomarkers of cardiovascular risk. Nevertheless, we have here presented an 
important second step in the development of a potentially clinically useful biomarker by 
taking it from the cross-sectional to the longitudinal level. 
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Figure 1. Hypertension Associated Cardiovascular Disease (HACVD) Urinary Proteomic 
Study population. 
*QC = quality control 
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Figure 2. Kaplan-Meier curve for the CAD238  model. Subjects were classified as < or > the 
mean value of the CAD238 classification factor. Log Rank (Mantel Cox) test statistic 5.35, 
p=0.021. 
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Table 1. Baseline Characteristics of Cases and Controls Passing Quality Control 
 
 Controls n=28 95%CI Cases n=32 95% CI P-value 
Mean age (yrs) 64±5 (62,66) 63±6 (61,65) 0.623 
Sex male 24 (86%)  29 (91%)  0.625 
Time in study 
(months) 
67±7 (64,70) 34±16 (28,40) 0.000 
SBP
†
 (mmHg) 161±20 (154,169) 162±17 (156,168) 0.874 
DBP
‡
 (mmHg) 92±9 (89,95) 93±11 (89,97) 0.588 
Total Cholesterol 
(mmol/L) 
5.7±0.9 (5.3,6.0) 5.6±1.0 (5.3,6.0) 0.958 
HDL
§
 (mmol/L) 1.3±0.4 (1.1,1.4) 1.3±0.4 (1.1,1.4) 0.977 
Creatinine 
(µmol/L) 
95±13 (90,100) 104±20 (97,111) 0.066 
Smoker 7 (25%)  6 (19%)  0.508 
Amlodipine 17 (61%)  16 (50%)  0.607 
Atorvastatin 11 (39%)  11 (34%)  0.581 
      
 
†SBP – systolic blood pressure, ‡DBP – diastolic blood pressure, §HDL – high-density 
lipoprotein 
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Table 2. The 25 urinary polypeptide markers showing significant differences between 
cases and controls in this study, which were part of the previously derived CAD238 panel 
PROTEIN NAME Swiss Prot/TrEMBLE name 
 
Extracellular matrix 
Collagen alpha-1(I) chain 
Collagen alpha-1(II) chain 
Collagen alpha-1(III) chain 
Collagen alpha-1(V) chain 
Collagen alpha-1 (XVII) chain 
Collagen alpha-1 (XVI) chain 
Collagen alpha-2(I) chain 
 
Haemostasis and erythropoiesis 
Fibrinogen beta chain 
Hemoglobin subunit beta 
Hemoglobin subunit delta 
 
Inflammation and immune response  
Beta-2-microglobulin 
Ig kappa chain C region 
Ig gamma-1 chain C region 
Ig lambda-2 chain C regions 
Signalling 
Membrane associated progesterone receptor component 1 
Prostaglandin-H2 D- isomerase 
Zinc finger protein 653 
 
 
 
CO1A1_HUMAN 
CO2A1_HUMAN 
CO3A1_HUMAN 
CO5A1_HUMAN 
COHA1_HUMAN 
COGA1_HUMAN 
CO1A2_HUMAN 
 
 
FIBB_HUMAN 
HBB_HUMAN 
HBD_HUMAN 
 
 
B2MG_HUMAN 
IGKC_HUMAN 
IGHG1_HUMAN 
LAC2_HUMAN 
 
 
PGRC1_HUMAN 
PTGDS_HUMAN 
ZN653_HUMAN 
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Other 
Beta 1,3 - galactosyltransferase 6 
Neurosecretory protein VGF 
 
 
B3GT6_HUMAN 
VGF_HUMAN 
Plexin domain-containing protein 2 PXDC2_HUMAN 
Polymeric-immunoglobulin receptor 
Retinol-binding protein 4 
Sodium/potassium - transporting ATPase subunit gamma 
Uromodulin 
Zinc-alpha-2-glycoprotein 
PIGR_HUMAN 
RET4_HUMAN 
ATNG_HUMAN 
UROM_HUMAN 
ZA2G_HUMAN 
 
